490 ARSENAL WAY, SUITE 200, WATERTOWN, MA
Reports First Quarter 2026 Financial Results and Provides Business Update
Financial Results, Press Release
Investor Presentation
Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones
Neumora Therapeutics Converts $2.5 Million Term Loan to Common Stock
Reports Third Quarter 2025 Financial Results and Provides Business Update
Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
S-3ASR
Prospectus filed pursuant to Rule 424(b)(4)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Amended Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Post-Effective Amendment to Registration Statement
Automatic Shelf Registration Statement